CBS News Investigates Untested Weight Loss Drug

CBS News has conducted an investigation into the availability and contents of an experimental weight loss drug, retatrutide, which is not approved by the Food and Drug Administration (FDA) and is currently undergoing clinical trials. The investigation revealed that the drug could be easily purchased from various sources without the need for medical consultations.

Retatrutide, also known as Reta, is being studied by pharmaceutical company Eli Lilly as a potential next-generation treatment for obesity. Despite its experimental status, CBS News was able to acquire the drug through multiple channels.

An online order for 20 milligrams of retatrutide was placed with Reset Wellness. The product arrived a week later, notably without any consultation with a health professional. Similarly, another purchase was made from Bodystreet Jupiter, where the drug was obtained after confirming Body Mass Index requirements. This order arrived just two days later, again without a consultation.

In Brooklyn, a CBS News reporter, Adam Yamaguchi, discovered a poster advertising retatrutide for sale over the counter at a local bodega. Yamaguchi was able to purchase a vial labeled 'Retatrutide' directly from a corner store, highlighting the ease of access to this experimental drug.

CBS News tested the vials marketed as retatrutide to determine their actual contents. The results of these tests were shared by Adam Yamaguchi on 'CBS Mornings,' though the specific findings of the tests were not detailed in the available reports.

This investigation raises significant concerns about the availability of unapproved drugs and the potential risks they pose to consumers who may purchase them without proper medical guidance. The findings underscore the importance of regulatory oversight and the need for consumers to exercise caution when considering experimental treatments.